COMPOUNDING FINDER
Tirzepatide is a dual GIP/GLP-1 receptor agonist prescribed for type 2 diabetes and chronic weight management. Delaware patients with a documented clinical need may be eligible for compounded tirzepatide.
Despite being a small state, Delaware benefits from proximity to Philadelphia-area compounding pharmacies and strong healthcare infrastructure. Compounding Finder helps Delaware patients compare options from licensed pharmacies.
Yes. The Delaware Board of Pharmacy oversees compounding. A valid prescription with clinical justification is required.
Typically $150 to $450 per month.